Trials / Recruiting
RecruitingNCT05445310
Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer
Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer: a Prospective Single-arm Study
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 114 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, single arm study to investigate the efficacy and safety furmonertinib 80mg/d as adjuvant treatment for 3 years post surgery of stage IA with high-risk factors and stage IB non-small cell lung cancer. A total of 114 patients would be enrolled. The primary endpoint is the disease-free survival rate at 3 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Furmonertinib | Furmonertinib 80mg/d |
Timeline
- Start date
- 2022-08-06
- Primary completion
- 2026-07-01
- Completion
- 2026-07-01
- First posted
- 2022-07-06
- Last updated
- 2023-02-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05445310. Inclusion in this directory is not an endorsement.